Technical Analysis for CYCN - Cyclerion Therapeutics, Inc.

Grade Last Price % Change Price Change
F 2.43 -5.81% -0.15
CYCN closed down 5.81 percent on Monday, April 19, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CYCN trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -5.81%
Stochastic Buy Signal Bullish -5.81%
Pocket Pivot Bullish Swing Setup -5.81%
Wide Bands Range Expansion -5.81%
Oversold Stochastic Weakness -5.81%
Wide Bands Range Expansion -2.80%
Oversold Stochastic Weakness -2.80%
Wide Bands Range Expansion -11.64%
Older End-of-Day Signals for CYCN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 10% about 15 hours ago
Fell Below Previous Day's Low about 16 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
Down 5% about 17 hours ago
Down 3% about 17 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cyclerion Therapeutics, Inc. Description

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its current portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Diseases Organ Systems Pharmacology Heart Failure Kidney Diseases Orphan Disease Orphan Diseases Diabetic Nephropathy Cardiomyopathy Central Nervous System Disease Central Nervous System Diseases Sickle Cell Disease Lung Diseases Heart Failure With Preserved Ejection Fraction

Is CYCN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 8.96
52 Week Low 2.18
Average Volume 351,166
200-Day Moving Average 4.20
50-Day Moving Average 3.70
20-Day Moving Average 2.96
10-Day Moving Average 2.72
Average True Range 0.29
ADX 23.31
+DI 15.00
-DI 28.32
Chandelier Exit (Long, 3 ATRs ) 3.60
Chandelier Exit (Short, 3 ATRs ) 3.18
Upper Bollinger Band 3.70
Lower Bollinger Band 2.22
Percent B (%b) 0.14
BandWidth 50.03
MACD Line -0.33
MACD Signal Line -0.30
MACD Histogram -0.0261
Fundamentals Value
Market Cap 82.53 Million
Num Shares 34 Million
EPS -4.74
Price-to-Earnings (P/E) Ratio -0.51
Price-to-Sales 25.71
Price-to-Book 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.84
Resistance 3 (R3) 2.84 2.71 2.77
Resistance 2 (R2) 2.71 2.61 2.71 2.74
Resistance 1 (R1) 2.57 2.54 2.51 2.57 2.72
Pivot Point 2.44 2.44 2.41 2.44 2.44
Support 1 (S1) 2.30 2.34 2.24 2.30 2.14
Support 2 (S2) 2.17 2.27 2.17 2.12
Support 3 (S3) 2.03 2.17 2.09
Support 4 (S4) 2.03